Observational studyTurkish journal of ophthalmology2026
Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study.
Observational study in Turkish journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Evolution of Myopia Control Spectacle Lenses in Türkiye.Turkish journal of ophthalmology · 2026Article
- Defocus-Incorporated Multiple-Segment (DIMS) Spectacle Lenses Versus Single-Vision Lenses for Myopia Control in a South-Eastern European Population.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study compared the 12-month real-world effectiveness of defocus incorporated multiple segments (DIMS) spectacle lenses, Myopi-X progressive addition lenses, and single-vision (SV) lenses in slowing myopia progression in children. Materials and Methods: This retrospective observational study included 385 eyes using one of the three spectacle types. Baseline age, spherical equivalent refraction (SER), and axial length (AL) were recorded. Twelve-month changes in SER and AL were analyzed using the Kruskal-Wallis test with Bonferroni-adjusted pairwise comparisons. Generalized estimating equations (GEE) were used to assess the effects of treatment group, age group, sex, and baseline AL group on SER and AL changes. Results: The study population consisted of 118 Myopi-X eyes (32.4%), 107 SV eyes (29.4%), and 139 DIMS eyes (38.2%). Baseline demographic and ocular characteristics (including age, sex, SER, AL, age group, and baseline AL group) were comparable among the groups (all p>0.05). After 12 months, mean SER progression was -0.35±0.34 diopters (D) in the Myopi-X group, -0.46±0.37 D in the SV group, and -0.24±0.33 D in the DIMS group (p<0.001). Mean AL elongation was 0.21±0.12 mm, 0.24±0.17 mm, and 0.17±0.16 mm, respectively (p=0.004). GEE analyses demonstrated a significant treatment effect for both SER and AL change (p<0.001 for both). The least progression occurred in the DIMS group, followed by Myopi-X, while the SV group showed the highest progression. Baseline AL group was the only significant predictor of AL elongation (β=0.210, 95% confidence interval: 0.189-0.231, p<0.001), with greater elongation in eyes with high baseline AL. Age group and sex did not significantly influence SER or AL outcomes. Conclusion: DIMS spectacle lenses were more effective than Myopi-X and SV lenses in reducing both refractive progression and axial elongation over 12 months. Baseline AL was a key determinant of axial growth, supporting the use of individualized risk assessment in pediatric myopia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.